Citi Downgrades Puma Biotechnology (PBYI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures muted as oil holds near April highs ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts PBYI Hot Sheet
Price: $10.85 --0%
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to Neutral with a price target of $24.00.
For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.
Shares of Puma Biotechnology closed at $19.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Downgrades Bank of Hawaii (BOH) to Market Perform, 'Risk/Reward More Balanced in the Current Backdrop'
- William Blair Downgrades Moderna (MRNA) to Market Perform
- StoneX Downgrades Surgery Partners (SGRY) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
